Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CPNE8 antisense RNA 1 (CPNE8-AS1) is a long non-coding RNA gene in humans, transcribed from the antisense strand of the CPNE8 locus on chromosome 12q12[8][9][10]. As a member of the lncRNA class, CPNE8-AS1 does not encode a protein product. Its expression has been associated with poor prognosis in patients with early-stage cervical cancer and potentially other malignancies[6][8]. lncRNAs like CPNE8-AS1 typically function by regulating the expression of their sense gene counterparts through various mechanisms, such as modulating transcription, altering mRNA stability by forming RNA-RNA hybrids, or recruiting RNA-binding proteins involved in gene regulation[5][11]. The specific biological function of CPNE8-AS1 appears to involve *antisense regulation of CPNE8*, but detailed molecular mechanisms remain to be clarified. There is no evidence that CPNE8-AS1 itself is a receptor, enzyme, or a direct therapeutic target, nor are there known drugs or targeted therapies acting on this lncRNA[8][10]. Its primary significance may be as a disease biomarker or potential modulator of cancer progression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CPNE8 antisense RNA 1 (CPNE8-AS1).